Search - tctmd.com

Displaying 21 - 40 of 401

Sort: Relevancy | Date

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

December 06, 2024

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

December 05, 2024

Palliative Care in HF: Practical Advice From the HFSA

News Daily News

Palliative Care in HF: Practical Advice From the HFSA

December 05, 2024

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

December 04, 2024

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

News Daily News

IVC Filter Lawsuits Expose Holes in FDA Oversight and Public Communication

December 03, 2024

TCTMD’s Top 10 Most Popular Stories for November 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2024

December 03, 2024

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

News Daily News

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

November 28, 2024

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 27, 2024

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

News Daily News

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Yael L. Maxwell

November 27, 2024

ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH

News Daily News

ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH

November 26, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

November 22, 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

News Conference News AHA 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

November 22, 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

November 21, 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

News Conference News AHA 2024

Talking Sex: CVD Patients Want to Hear More From Clinicians

November 20, 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.